XLO vs NKTX vs FATE vs IMVT

For growth investors, Xilio Therapeutics, Inc.

(XLO) is the stronger pick with 589. 9% revenue growth year-over-year, versus -51. 2% for Fate Therapeutics, Inc. (FATE). Analysts rate Xilio Therapeutics, Inc. (XLO) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus XLO's -96. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xilio Therapeutics, Inc.

(XLO) is the lower-risk stock at 1. 09β versus Fate Therapeutics, Inc. 's 2. 17β — meaning FATE is approximately 100% more volatile than XLO relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 38% for Fate Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xilio Therapeutics, Inc.

(XLO) is pulling ahead at 589. 9% versus -51. 2% for Fate Therapeutics, Inc. (FATE). On earnings-per-share growth, the picture is similar: Xilio Therapeutics, Inc. grew EPS 72. 5% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Xilio Therapeutics, Inc.

(XLO) is the more profitable company, earning 0. 0% net margin versus -20. 5% for Fate Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NKTX leads at 0. 0% versus -22. 2% for FATE. At the gross margin level — before operating expenses — XLO leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Xilio Therapeutics, Inc.

(XLO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 09)). Nkarta, Inc. (NKTX) carries a higher beta of 2. 07 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XLO: -96. 5%, NKTX: -93. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XLO is a small-cap high-growth stock; NKTX is a small-cap quality compounder stock; FATE is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.